This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Indivior Pharmaceuticals Future Growth
Future criteria checks 4/6
Indivior Pharmaceuticals is forecast to grow earnings and revenue by 42.5% and 2% per annum respectively. EPS is expected to grow by 41.7% per annum. Return on equity is forecast to be 128.3% in 3 years.
Key information
42.5%
Earnings growth rate
41.66%
EPS growth rate
Pharmaceuticals earnings growth
24.3%
Revenue growth rate
2.0%
Future return on equity
128.27%
Analyst coverage
Good
Last updated
27 Jan 2026
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
MUN:2IVB - Analysts future estimates and past financials data (USD Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
1,227
N/A
479
503
2
12/31/2027
1,205
406
441
455
7
12/31/2026
1,145
349
419
450
7
12/31/2025
1,191
225
127
193
7
9/30/2025
1,180
124
117
177
N/A
6/30/2025
1,173
103
171
218
N/A
3/31/2025
1,170
-12
115
148
N/A
12/31/2024
1,188
2
5
36
N/A
9/30/2024
1,182
-91
-245
-213
N/A
6/30/2024
1,147
-248
-247
-194
N/A
3/31/2024
1,124
-112
-351
-301
N/A
12/31/2023
1,093
-129
-353
-300
N/A
9/30/2023
1,042
-235
-89
-52
N/A
6/30/2023
1,002
-59
-22
-11
N/A
3/31/2023
947
-50
23
35
N/A
12/31/2022
901
-44
-9
-4
N/A
9/30/2022
882
166
176
181
N/A
6/30/2022
838
152
160
145
N/A
3/31/2022
818
166
175
189
N/A
12/31/2021
791
205
339
353
N/A
9/30/2021
753
156
101
115
N/A
6/30/2021
725
139
81
115
N/A
3/31/2021
674
95
39
42
N/A
12/31/2020
647
-148
-197
-193
N/A
9/30/2020
595
-190
-84
-82
N/A
6/30/2020
634
-152
-70
-69
N/A
3/31/2020
700
-95
-131
-130
N/A
12/31/2019
785
134
148
151
N/A
9/30/2019
889
213
217
200
N/A
6/30/2019
935
254
N/A
275
N/A
3/31/2019
988
248
N/A
413
N/A
12/31/2018
1,005
275
N/A
303
N/A
9/30/2018
1,033
106
N/A
276
N/A
6/30/2018
1,064
67
N/A
210
N/A
3/31/2018
1,083
71
N/A
260
N/A
12/31/2017
1,093
58
N/A
295
N/A
9/30/2017
1,087
281
N/A
360
N/A
6/30/2017
1,080
81
N/A
409
N/A
3/31/2017
1,065
65
N/A
370
N/A
12/31/2016
1,058
35
N/A
407
N/A
9/30/2016
1,047
-6
N/A
326
N/A
6/30/2016
1,028
191
N/A
283
N/A
3/31/2016
1,021
201
N/A
252
N/A
12/31/2015
1,014
228
N/A
320
N/A
9/30/2015
1,037
268
N/A
300
N/A
6/30/2015
1,058
314
N/A
369
N/A
3/31/2015
1,085
361
N/A
530
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2IVB's forecast earnings growth (42.5% per year) is above the savings rate (1.6%).
Earnings vs Market: 2IVB's earnings (42.5% per year) are forecast to grow faster than the German market (16.6% per year).
High Growth Earnings: 2IVB's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 2IVB's revenue (2% per year) is forecast to grow slower than the German market (6.1% per year).
High Growth Revenue: 2IVB's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2IVB's Return on Equity is forecast to be very high in 3 years time (128.3%).
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/01/28 19:42
End of Day Share Price
2026/01/08 00:00
Earnings
2025/09/30
Annual Earnings
2024/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Indivior Pharmaceuticals, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.